An analysis of phase 3 trials found tamoxifen significantly reduced 15-year ipsilateral breast recurrence in patients with ...

Today, women with oestrogen-sensitive breast cancer receive anti-hormonal therapy. Researchers now show that postmenopausal ...

These findings support tamoxifen as an effective adjuvant therapy for reducing recurrence in women with "good-risk" DCIS who opt to skip RT. Read on!

Weekly administration of prophylactic tamoxifen is much less effective than the standard daily regimen in preventing the adverse breast effects induced by bicalutamide. Bicalutamide monotherapy is ...

For patients with “good-risk” ductal carcinoma in situ (DCIS) who underwent breast- conserving surgery and did not receive radiotherapy, tamoxifen significantly decreased the risk of recurrence in the ...

Today, women with estrogen-sensitive breast cancer receive anti-hormonal therapy. Researchers now show that postmenopausal ...

Preclinical studies and early clinical trials have shown that the anticancer agent tamoxifen, a relatively selective PKC inhibitor that can cross the blood–brain barrier, exerts an antimanic ...

Science News: "Younger women generally have a higher risk of recurrence than older postmenopausal women, but most studies on ...

Wright further emphasized that knowing the risk of recurrence, with and without tamoxifen, for patients who choose to forgo radiotherapy can help patients most effectively weigh the risks and benefits ...

For patients with "good-risk" ductal carcinoma in situ (DCIS) who underwent breast- conserving surgery and did not receive ...